Blogs

Why Lovenox (Not a True Biosimilar) Creates a Precedent for Biosimilars

Will Chemical Engineers Save Pharma?

You Can't Duct Tape Quality: FDA Issues Consent Decree against Actavis Totowa

Will the High Costs of Analytics Permit Future Cases of Heparin Contamination?

Generics vs. Namebrand Drugs: Case Studies in Process and Ingredient Variability?

Baxter’s Recalled Heparin Might Be Linked to Uninspected Chinese Plant

Seen and Heard at IFPAC

This Could Dampen Enthusiasm for Biogenerics

Notes from ISPE 2007 - Lean Principles Guide Teva’s New Plant in Jerusalem